Precigen Posts Q2 Profit of 5 Cents Per Share, First Quarterly Profit
PGEN has more than doubled off its 52-week low of $1.7.
Summary
Precigen reported Q2 EPS of 5 cents, marking its first profitable quarter. This follows strong Q1 results driven by $21.6M in Papzimeos revenue. The profit signals the drug's commercial traction is translating to the bottom line. With the stock near its 52-week high, this confirms the turnaround narrative. Watch for management commentary on sustainability and cash burn trends.
Updates
· SEC 8-K — PAPZIMEOS net revenue was $53.1 million in Q2, more than double the prior quarter; total revenue $55.0 million; net income $20.1 million; cash $38.7 million; expects cash flow break-even by end of 2026.
At the time of this announcement, PGEN was trading at $7.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $1.70 to $6.80. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.